Genentech has received FDA approval for Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of HER2-positive metastatic breast cancer (mBC) in patients that have received prior Herceptin and chemotherapy treatment. Kadcyla, an antibody-drug conjugate (ADC), is a new kind of targeted cancer medicine that can attach to certain types of cancer cells and deliver chemotherapy directly to them. Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC.   “Kadcyla is an antibody-d...